MedPath

InTerlaboratory Evaluation of a GastroIntestinal Activity Ergometertest in Non-intense Trained PersOns

Withdrawn
Conditions
gastrointestinal activity
10017969
intestinal barrier function
Registration Number
NL-OMON43135
Lead Sponsor
Hogeschool Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
16
Inclusion Criteria

• Male
• Generally healthy
• Recreational athlete with at least two years of cycling experience of at least twice a week
• 18-35 years old
• Meeting criteria of valid max-test
• Body mass index (BMI) 20-25 kg/m2
• Veins suitable for blood sampling at inspection

Exclusion Criteria

-Known symptoms of immune diseases such as diabetes, celiac disease, gastric disease
-Known symptoms of intestinal diseases such as Crohn*s disease, colitis ulcerosa, irritable bowel syndrome fibrosis
-Smoking
-Use of hard drugs
--Chronic use of NSAIDs: aspirin, ibuprofen, etc.
-Drugs for gastric and/or intestinal function
- Participation in other scientific studies
-Blood donation during the last six weeks prior to the start of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameters are the relative changes in blood, urine and saliva<br /><br>of markers of intestinal barrier function (iFABP, lactulose/rhamnose ratio,<br /><br>zonulin), immune responsiveness (e.g. leukocytes) and of markers reflecting<br /><br>general physiological changes (e.g. cortisol). These parameters were most<br /><br>clearly affected in the study GRINTA!. As a new parameter we include<br /><br>RNA-profiling of blood cells, as indication of functional alterations in<br /><br>leukocytes. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The relative changes in blood, urine and saliva of markers of intestinal<br /><br>barrier function (iFABP, lactulose/rhamnose ratio, zonulin), immune<br /><br>responsiveness (e.g. leukocytes) and markers reflecting general physiological<br /><br>changes (e.g. cortisol) in an intermediate-intense (moderate) exercise. </p><br>
© Copyright 2025. All Rights Reserved by MedPath